Home / Data / Women's Health Trial Tracker Women's Health Trial Tracker Women's Health Trial Tracker organizes records from ClinicalTrials.gov API v2 into a static table for transparent comparison. It preserves official source links and dates, marks missing enrichment, and adds deterministic grouping, change, recency, trend, or significance fields only where the documented inputs support them, without recommendations or unsupported claims.
Records 5,000
Last changed 08/26/2026
Update schedule 55 1 * * * UTC
Coverage 05/26/2000–08/25/2026 Record Record Date Vuga Group Change Status Recency Days Public Significance Score Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial 02/14/2022 INTERVENTIONAL unchanged 1,654.85 0 Axillary Lymph Node Treatment Guided by Naocarbon Tracing After Neoadjuvant Chemotherapy 02/15/2022 INTERVENTIONAL unchanged 1,653.85 0 Evaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer 02/15/2022 INTERVENTIONAL unchanged 1,653.85 0 Evolutionary Nutrition Pilot: Enhancing Fetal Growth and Brain Development 02/16/2022 INTERVENTIONAL unchanged 1,652.85 0 Retrospective Study of Brachytherapy 02/16/2022 OBSERVATIONAL unchanged 1,652.85 0 Imaging Sodium and Lymphatics in Lymphedema 02/16/2022 OBSERVATIONAL unchanged 1,652.85 0 Efficacy of Strategies Involving Self-sampling to Reach Women Not Participating in Regular Cervical Cancer Screening 02/17/2022 INTERVENTIONAL unchanged 1,651.85 0 Epidemiology of Sexually Transmitted Infections and Its iMpAcT on fEmale Infertility 02/17/2022 OBSERVATIONAL unchanged 1,651.85 0 Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage 02/17/2022 INTERVENTIONAL unchanged 1,651.85 0 Deep Neural Network Stratification for Use Detecting Endometriosis in Women Affected by Chronic Pelvic Pain (EndoCheck) 02/18/2022 OBSERVATIONAL unchanged 1,650.85 0 Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy 02/18/2022 INTERVENTIONAL unchanged 1,650.85 0 Prospective Evaluation of Pathways for Preterm Birth 02/18/2022 OBSERVATIONAL unchanged 1,650.85 0 Gonadotropin-releasing Hormone Agonist (GnRHa) Plus Letrozole In Young Women With Early Endometrial Cancer 02/18/2022 INTERVENTIONAL unchanged 1,650.85 0 The Cardiovascular Impact of Hot Flushes 02/22/2022 OBSERVATIONAL unchanged 1,646.85 0 Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy 02/22/2022 INTERVENTIONAL unchanged 1,646.85 0 A Study to Analyze Data on Metastatic Ovarian Cancer Using Multi-omics 02/23/2022 OBSERVATIONAL unchanged 1,645.85 0 Mapping and Quantifying Lymphatic Drainage of the Arm's Alternate Pathway 02/23/2022 OBSERVATIONAL unchanged 1,645.85 0 Pilot Study of Suction as a Mechanism of IUD Expulsion With Concomitant Menstrual Cup Use 02/24/2022 INTERVENTIONAL unchanged 1,644.85 0 Efficacy/Safety of Midurethral Sling 02/24/2022 INTERVENTIONAL unchanged 1,644.85 0 MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients. 02/24/2022 INTERVENTIONAL unchanged 1,644.85 0 Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features 02/24/2022 INTERVENTIONAL unchanged 1,644.85 0 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma 02/25/2022 INTERVENTIONAL unchanged 1,643.85 0 RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer 02/25/2022 INTERVENTIONAL unchanged 1,643.85 0 Heparin Solution Versus Anti-adhesion Barrier Gel for Intrauterine Adhesions Prevention After Operative Hysteroscopy 02/25/2022 INTERVENTIONAL unchanged 1,643.85 0 A Study of XZP-3287 in Combination With Letrozole/Anastrozole in Patients With Advanced Breast Cancer 02/25/2022 INTERVENTIONAL unchanged 1,643.85 0 Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer 02/25/2022 INTERVENTIONAL unchanged 1,643.85 0 Factors Influencing Breast Cancer Resection Volumes And Their Impact on Treatment Outcome (FIBRATIO) 02/25/2022 OBSERVATIONAL unchanged 1,643.85 0 Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes 02/28/2022 OBSERVATIONAL unchanged 1,640.85 0 Breast Cancer Prevention and Screening Membership 02/28/2022 INTERVENTIONAL unchanged 1,640.85 0 Time Restricted Eating During Chemotherapy for Breast Cancer 02/28/2022 INTERVENTIONAL unchanged 1,640.85 0 Delivering Empowering Conversations About Obstetric Regional Anesthesia for Underserved Minorities 03/02/2022 INTERVENTIONAL unchanged 1,638.85 0 A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years 03/02/2022 INTERVENTIONAL unchanged 1,638.85 0 Uterine Transplant for Women With Absolute Uterine Factor Infertility (AUFI) 03/02/2022 INTERVENTIONAL unchanged 1,638.85 0 The Efficiency for Stage II-III HR+/HER2+ Early Breast Cancer Patient With Standard Neoadjuvant Therapy in Real World. 03/02/2022 OBSERVATIONAL unchanged 1,638.85 0 The Effect of Intramyometrial Injection of Terlipressin Versus Carbitocin on Hemoglobin and Blood Loss During Open Myomectomy Operations Without Using Haemostatic Tourniquets 03/04/2022 INTERVENTIONAL unchanged 1,636.85 0 mHealth India Postnatal Health Intervention Effectiveness 03/07/2022 INTERVENTIONAL unchanged 1,633.85 0 Organic Diet in Pregnancy and Risk Markers of Health Effects (The OrgDiet Project) 03/07/2022 INTERVENTIONAL unchanged 1,633.85 0 CBT for Postpartum Depression and Infant Emotion Regulation 03/08/2022 INTERVENTIONAL unchanged 1,632.85 0 Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. 03/09/2022 INTERVENTIONAL unchanged 1,631.85 0 Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer 03/14/2022 INTERVENTIONAL unchanged 1,626.85 0 Adjuvant Concurrent Chemoradiotherapy Versus Radiotherapy in Early-stage Cervical Cancer Patients 03/14/2022 INTERVENTIONAL unchanged 1,626.85 0 Neurofeedback Based on Near-infrared Spectroscopy as a Therapy for Food Addiction in Obese Subjects. 03/14/2022 INTERVENTIONAL unchanged 1,626.85 0 Wearable Enhanced Fitness Tracking for Metastatic Breast Cancer Patients Using Endocrine Treatment and Palbociclib 03/14/2022 INTERVENTIONAL unchanged 1,626.85 0 Functional Evaluation After Breast Reconstruction With a Minimally Invasive Latissimus Dorsi Flap Following Radical Surgery for Breast Cancer. 03/14/2022 INTERVENTIONAL unchanged 1,626.85 0 Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation 03/15/2022 INTERVENTIONAL unchanged 1,625.85 0 HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness 03/15/2022 OBSERVATIONAL unchanged 1,625.85 0 Use of Glubran 2 ® in Axillary Lymphadenectomy Without Drain 03/15/2022 INTERVENTIONAL unchanged 1,625.85 0 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) 03/16/2022 INTERVENTIONAL unchanged 1,624.85 0 Effect of HPV Integration on Prognosis of Young Women With CIN2 in China 03/16/2022 OBSERVATIONAL unchanged 1,624.85 0 Examining the Effects of Estradiol on Neural and Molecular Response to Reward 03/16/2022 INTERVENTIONAL unchanged 1,624.85 0
Source U.S. National Library of Medicine, ClinicalTrials.gov API v2 · official record · retrieved 08/26/2026 · upstream last modified 08/26/2026
Licence United States government work; public domain unless the source record says otherwise. Source: U.S. National Library of Medicine
Required notice Study records are informational and do not provide diagnosis, treatment advice, or an assessment of individual risk. What we add We compute Vuga Group, Change Status, Recency Days, Public Significance Score using the documented compute method. · methodology